Tokyo - Delayed Quote JPY

MediPal Holdings Corporation (7459.T)

2,474.00

-12.50

(-0.50%)

At close: May 9 at 3:30:00 PM GMT+9

Notice of Orphan Drug Designation for JR-446 for Mucopolysaccharidosis Type IIIB by the U.S. FDA

TOKYO & HYOGO, Japan, May 07, 2025--MEDIPAL and JCR announced that the U.S. FDA granted orphan drug designation (ODD) to JR-446, an investigational drug for the treatment of MPS IIIB.

Business Wire 3 days ago

JCRRF

MAHLY

MEPDF
MEDIPAL HOLDINGS CORPORATION and JCR Pharmaceuticals Announce Initiation of First Dosing in Phase I/II Clinical Trial of JR-446 for Mucopolysaccharidosis Type IIIB in Japan

TOKYO & HYOGO, Japan, December 05, 2024--JCR and MEDIPAL announced the initiation of the Phase I/II clinical trial of JR-446 in Japan following dosing of the first individual from the trial.

Business Wire 5 months ago

JCRRF

MAHLY

MEPDF

Performance Overview

Return	7459.T	Nikkei 225 (^N225)
YTD	+5.23%	-5.99%
1-Year	+2.68%	-1.50%
3-Year	+19.89%	+42.49%